Switzerland

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis’ Ilaris [Canakinumab] Unexpectedly Slashes Need For Joint Replacements From Osteoarthritis In Key Study

Lead Product(s): Canakinumab

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ilaris

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2020

Details:

In a study of Ilaris in 10,000 patients with a history of heart attack it is found that people taking the drug had 40% to 47% lower rates of total knee or hip replacements than did those taking a placebo.

Idorsia Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Idorsia Successfully Completes the Offering of New Shares Thereby Securing Funding for the Company’s Growth Plan

Lead Product(s): Aprocitentan

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $341.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering May 20, 2020

Details:

The net proceeds from this offering will help Idorsia to prepare to launch its first commercial product and continue to fund the development of its pipeline candidates including aprocitentan, clazosentan and lucerastat, as well as its early-stage and preclinical pipeline.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran

Lead Product(s): Inclisiran

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2020

Details:

Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis announces NEJM publication of three pivotal trials

Lead Product(s): Inclisiran

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD).

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Novartis Pharmaceuticals Corporation

Novartis’ Ilaris [Canakinumab] Unexpectedly Slashes Need For Joint Replacements From Osteoarthritis In Key Study

Idorsia Pharmaceuticals

Idorsia Successfully Completes the Offering of New Shares Thereby Securing Funding for the Company’s Growth Plan

Novartis Pharmaceuticals Corporation

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran

Novartis Pharmaceuticals Corporation

Novartis announces NEJM publication of three pivotal trials